Advances in Vaccines, Checkpoint Blockade, and Chimeric Antigen Receptor-Based Cancer Immunotherapeutics

被引：0

作者：

Agarwal, Disha ^{[1
]}

Sharma, Gaurav ^{[1
]}

Khadwal, Alka ^{[2
]}

Toor, Devinder ^{[3
]}

Malhotra, Pankaj ^{[2
]}

机构：

[1] Postgrad Inst Med Educ & Res, Dept Translat & Regenerat Med, 5th Floor Res Block B Sect 12, Chandigarh 160012, India

[2] Postgrad Inst Med Educ & Res, Dept Clin Hematol & Med Oncol, Chandigarh, India

[3] Amity Univ Uttar Pradesh, Amity Inst Virol & Immunol, Noida, India

来源：

CRITICAL REVIEWS IN IMMUNOLOGY | 2024年 / 45卷 / 01期

关键词：

vaccines; cancer; immunotherapy; CTLA-4; PD-1; CAR-T cells; CAR-NK cells; immune surveillance; immune exhaustion; MESSENGER-RNA VACCINES; NATURAL-KILLER-CELLS; T-CELLS; DENDRITIC CELLS; NK-92; CELLS; CD28; GENERATION; RESISTANCE; THERAPY; PD-1;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Increase in cancer cases and research driven by understanding its causes, facilitated development of novel targeted immunotherapeutic strategies to overcome nonspecific cytotoxicity associated with conventional chemotherapy and radiotherapy. These target specific immunotherapeutic regimens have been evaluated for their efficacy, including: (1) vaccines harnessing tumor specific/associated antigens, (2) checkpoint blockade therapy using monoclonal antibodies against PD1, CTLA-4 and others, and (3) adoptive cell transfer approaches viz. chimeric antigen receptor (CAR)-cellbased therapies. Here, we review recent advancements on these target specific translational immunotherapeutic strategies against cancer/s and concerned limitations.

引用

页码：65 / 80

页数：16

共 50 条

[21] Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Yilmaz, Ahmet
Cui, Hanwei
Caligiuri, Michael A.
Yu, Jianhua
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
[22] Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer
Yan, Wenying
Hu, Hongmei
Tang, Biao
ONCOTARGETS AND THERAPY, 2019, 12 : 8015 - 8022
[23] Immunotherapy for the Treatment of Breast Cancer: Checkpoint Blockade, Cancer Vaccines, and Future Directions in Combination Immunotherapy
McArthur, Heather L.
Page, David B.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 922 - 933
[24] Advances in manufacturing chimeric antigen receptor immune cell therapies
Ramamurthy, Apoorva
Tommasi, Anna
Saha, Krishanu
SEMINARS IN IMMUNOPATHOLOGY, 2024, 46 (05)
[25] Advances in Chimeric Antigen Receptor Immunotherapy for Neuroblastoma
Heczey, Andras
Louis, Chrystal U.
DISCOVERY MEDICINE, 2013, 16 (90) : 287 - 294
[26] Advances in chimeric antigen receptor T cells
Beyar-Katz, Ofrat
Gill, Saar
CURRENT OPINION IN HEMATOLOGY, 2020, 27 (06) : 368 - 377
[27] Chasing cancer with chimeric antigen receptor therapy
Pham, Christina D.
Mitchell, Duane A.
IMMUNOTHERAPY, 2012, 4 (04) : 365 - 367
[28] Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
Emens, Leisha A.
EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (12) : 1597 - 1611
[29] Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy
Rashidijahanabad, Zahra
Huang, Xuefei
SEMINARS IN IMMUNOLOGY, 2020, 47
[30] Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer
He, Qingjie
Hu, Haibo
Yang, Fan
Song, Dong
Zhang, Xiaoling
Dai, Xiangpeng
BIOMEDICINE & PHARMACOTHERAPY, 2023, 162

← 1 2 3 4 5 →